ClinicalTrials.gg
CompletedNCT05351047Updated Aug 7, 2023

A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

A Phase 1 interventional study of AZD2373 subcutaneous injection and Placebo in Healthy Volunteers, sponsored by AstraZeneca. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-07.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a Phase 1 study to assess the the safety, tolerability and pharmacokinetics (PK) of AZD2373, following subcutaneous (SC) administration of multiple ascending doses (MAD) of AZD2373 in healthy male participants of sub-Saharan West African ancestry.

Read the detailed description

This study will be conducted as a single center, randomized, placebo-controlled, single-blind study to assess the effect of AZD2373 following multiple ascending dose sequential group design administrations to healthy male participants of sub Saharan West African ancestry.

The study will consist of up to 5 cohorts

Up to 40 male participants aged 18 to 55 years (inclusive), at time of informed consent, will be randomized. The MAD study subjects will be selected based on the results of the pre-screening study with regards to APOL1 allele status.

For all cohorts, 8 participants will participate in each cohort.

The expected duration for any participant participating in the study is approximately 14 to 16 weeks, excluding an up to 35-day Screening Period.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Phase 1
  • Randomized
  • Single-blind
  • Placebo controlled
  • AZD2373
  • Multiple Ascending Dose
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated, written prior to any study specific procedures.
  2. Healthy male participants of sub-Saharan West African ancestry aged 18 to 55 years (inclusive, at time of informed consent)
  3. Have a between 18.5 and 35 kg/m2 (inclusive) and weigh at least 50 kg and no more than 120 kg (inclusive) at screening.
  4. Provision of signed, written and dated informed consent and completed mandatory genotyping in the pre-screening study .

Exclusion criteria

Exclusion Criteria:

  1. Participants with known ancestry outside of sub-Saharan West Africa.
  1. History of any disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  1. History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
  1. History of any chronic skin disease, auto-immunological diseases and allergic diseases of any etiology.
  1. Any clinically important illness, medical/surgical procedure or trauma within 4 weeks prior to administration of IMP on Study Day 1.
  1. Participant has clinical signs and symptoms consistent with SARS-CoV-2 or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or on admission.

. 7. Participant who had a severe course of COVID-19.

  1. Participant has a positive viral RNA test result for SARS-CoV-2 before randomization.
  1. Any laboratory values with the following deviations:
  1. or AST greater than and clinically significant as determined by the PI.
  2. WBC count \< 3.0 x 109/L.
  3. below LLN.
  4. Total > ULN.
  5. count below LLN.

    10, Any clinically important abnormalities in clinical chemistry, hematology or urinalysis results, as judged by the PI.

    1. Any positive result on Screening for serum surface antigen, antibody and .
    1. Any abnormal vital signs, after 10 minutes supine rest.
    1. Any clinically significant abnormalities in rhythm, conduction or morphology of the resting and any clinically significant abnormalities in the 12-lead ECG as considered by the Investigator that may interfere with the interpretation of changes, including abnormal ST-T-wave morphology.
    1. Known or suspected history of drug abuse as judged by the PI.
    1. Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the previous 3 months.
    1. History of alcohol abuse or excessive intake of alcohol as judged by the PI.
    1. Positive screen for drugs of abuse or cotinine (nicotine) at Screening or admission to the Clinical Unit or positive screen for alcohol on admission to the Clinical Unit prior to administration of the IMP on Study Day 1.
    1. History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to AZD2373.
    1. Excessive intake of caffeine-containing drinks or food as judged by the PI.
    1. Use of any prescribed or non-prescribed medication including antacids, analgesics, herbal remedies, mega-dose vitamins or minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long t½..
    1. Plasma donation within one month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months prior to the Screening Visit.
    1. Has received another new chemical entity within 3 months prior to administration of the IMP on Study Day.
    1. Participants who have previously received AZD2373. Participants carrying a G2 allele who were enrolled in the AZD2373 SAD study but did not receive AZD2373 are not excluded.
    1. History of severe infection, chronic or recurrent infectious disease or ongoing febrile illness within 30 days prior to Screening.
    1. Evidence of CKD and/or proteinuria.
    1. Blood dyscrasias with increased risk of bleeding including idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura or symptoms of increased risk of bleeding (frequent bleeding gums or nose bleeds).
    1. Involvement of any AstraZeneca or Clinical Unit employee or their close relatives.
    1. Judgment by the PI that the participant should not participate in the study if they have any ongoing or recent (i.e., during the Screening Period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.
    1. Participants who are vegans or have medical dietary restrictions that would make them unable to comply with the diet provided for the in-house Clinical Unit stays.
    1. Participants who cannot communicate reliably with the PI.
    1. Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
    1. History of Trypanosomiasis or Leishmaniasis.
    1. Participants with a planned visit to a tropical or subtropical region within 10 weeks after administration of the IMP or 5 x t½ of AZD2373 (whichever is longer).
    1. Participants with sickle cell disease will be excluded but not individuals with heterozygous sickle cell trait.

    In addition, any of the following is regarded as a criterion for exclusion from the APOL1 genotyping research (APOL1 genotyping to be assessed during the pre-screening study):

    1. Previous bone marrow transplant.
    1. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the APOL1 genotyping sample collection.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Once weekly dosing for 4 weeks (Dosing Days 1, 8, 15 and 22) OR Once weekly dosing for 6 weeks (Dosing Days 1, 8, 15, 22, 29 and 36) randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 1 (6 subjects) or matching placebo (2 subjects).

    Drug: AZD2373 subcutaneous injection · Drug: Placebo

  • Experimental
    Cohort 2

    Once weekly for 6 weeks dosing on Days 1, 8, 15, 22, 29 and 36 randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 2 (6 subjects) or matching placebo (2 subjects).

    Drug: AZD2373 subcutaneous injection · Drug: Placebo

  • Experimental
    Cohort 3

    Three times weekly for 6 weeks dosing each week on Days 1, 3, and 5 randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 3 (6 subjects) or matching placebo (2 subjects).

    Drug: AZD2373 subcutaneous injection · Drug: Placebo

  • Experimental
    Cohort 4 (optional)

    Between one to seven doses each week for 6 weeks randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 4 (6 subjects) or matching placebo (2 subjects).

    Drug: AZD2373 subcutaneous injection · Drug: Placebo

  • Experimental
    Cohort 5 (optional)

    Between one to seven doses each week for 6 weeks randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 5 (6 subjects) or matching placebo (2 subjects).

    Drug: AZD2373 subcutaneous injection · Drug: Placebo

Interventions

  • Randomized subjects will receive multiple ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5).

  • DrugPlacebo

    Randomized subjects will receive a multiple ascending dose of placebo (saline solution) by SC injection.

06

What researchers measure

Primary outcomes

  1. Number of subjects with adverse events and/or abnormal findings in vital signs, and/or clinical laboratory assessments and/or physical examination and/or electrocardiogram (ECG) evaluation and/or injection site reactions

    To assess the safety and tolerability of subcutaneous (SC) multiple ascending dose (MAD) administrations of AZD2373.

    Time frame: Up to 21 weeks (From Screening to Final Visit)

Secondary outcomes

  1. AUCinf

    To characterize the PK of AZD2373 following SC MAD administrations of AZD2373

    Time frame: Up to 16 weeks (From Visit 2 to Final Visit)

  2. AUCt

    To characterize the PK of AZD2373 following SC MAD administrations of AZD2373

    Time frame: Up to 16 weeks (From Visit 2 to Final Visit)

  3. AUCτ

    To characterize the PK of AZD2373 following SC MAD administrations of AZD2373

    Time frame: Up to 16 weeks (From Visit 2 to Final Visit)

  4. Cmax

    To characterize the PK of AZD2373 following SC MAD administrations of AZD2373

    Time frame: Up to 16 weeks (From Visit 2 to Final Visit)

  5. tmax

    To characterize the PK of AZD2373 following SC MAD administrations of AZD2373

    Time frame: Up to 16 weeks (From Visit 2 to Final Visit)

  6. t1/2

    To characterize the PK of AZD2373 following SC MAD administrations of AZD2373

    Time frame: Up to 16 weeks (From Visit 2 to Final Visit)

  7. Percent change in plasma APOL1 protein from baseline

    To assess the effect of SC MAD administrations of AZD2373 on plasma concentrations of APOL1 protein

    Time frame: Up to 21 weeks (From Screening to Final Visit)

  8. APOL1 allele status

    To determine APOL1 G0, G1, G2 allele genotype status in all study participants

    Time frame: Days -35 to -1 (Screening period)

07

Study locations

1 site
  • Research Site
    Brooklyn, Maryland 21225, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Jul 2023, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2022
First posted
Apr 28, 2022
StartActual
Apr 4, 2022
Primary completionActual
Jul 6, 2023
CompletionActual
Jul 6, 2023
Last update
Aug 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05351047
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Apr 28, 2022
Start date
Apr 4, 2022
Primary completion
Jul 6, 2023
Completion
Jul 6, 2023
Last update
Aug 7, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Opemalirsen

Start the discussion